<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02797067</url>
  </required_header>
  <id_info>
    <org_study_id>ESWL-pancreatitis</org_study_id>
    <nct_id>NCT02797067</nct_id>
  </id_info>
  <brief_title>Rectal Indomethacin to Prevent Post ESWL-pancreatitis</brief_title>
  <acronym>RIPEP</acronym>
  <official_title>Rectally Administered Indomethacin to Prevent Post-ESWL-pancreatitis (RIPEP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether rectal indomethacin reduces the incidence of
      post-ESWL pancreatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a prospective, double-blind, randomized controlled trial. Patients with painful chronic
      pancreatitis and pancreatic stones (&gt; 5 mm in diameter) who are treated with ESWL at Changhai
      Hospital will be randomly allocated to indomethacin or placebo therapy before the procedure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the incidence of post-ESWL pancreatitis</measure>
    <time_frame>up to 1 months</time_frame>
    <description>TPatients were identified as post-ESWL pancreatitis if meeting two out of three criteria: pain consistent with acute pancreatitis; amylase or lipase&gt;3 times normal limit; characteristic findings on imaging, in according to the Revised Atlanta International consensus.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the incidence and severity of asymptomatic hyperamylasemia and other post-ESWL complications</measure>
    <time_frame>up to 1 months</time_frame>
    <description>Asymptomatic hyperamylasemia was defined as an increase in serum amylase compared with pre-ESWL levels and beyond the upper limit of the normal range but showing no related symptoms. Serum amylase will be measured in all study patients at 3 and 24 hours after the procedure and subsequently at clinical discretion.
Other post-ESWL complications including bleeding, infection, steinstrasse and perforation.
Bleeding is related to clinical evidence，the level of hemoglobin ( measured at 24 hours after the procedure and at clinical discretion) and treatments.
Infection is related to temperature and treatment. Steinstrasse is related to abdominal pain degree and the combination of other complications.
Perforation is related to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the severity of Post-ESWL pancreatitis measured as consensus definitions for the major complications of ERCP（endoscopic retrograde cholangiopancreatography ）</measure>
    <time_frame>up to 1 months</time_frame>
    <description>Post-ESWL complications are also stratified as mild, moderate and severe depending mainly on the length of hospitalization and the need for invasive treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Relative risks in the subgroup of potential risk factors for post -ESWL pancreatitis will be assessed by SPSS（Statistical Product and Service Solutions，a statistical software）.</measure>
    <time_frame>up to 1 months</time_frame>
    <description>Potential risk factors including sex, steatorrhea, pancreas divisum, frequent attack of acute pancreatitis (≥ 1/year), diabetes, CBD（common bile duct） stenosis, alcohol consumption, multiple stones, position (the 30°-right supine position) and shock wave frequency ≥100/min.These will be assess to determine whether the treatment effect differ in these pre-specified factors.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1428</enrollment>
  <condition>Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Indomethacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be randomized to receive a 100-mg indomethacin suppository 30 min before ESWL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glycerin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be randomized to receive either a 100-mg identical-appearing placebo (glycerin suppository) 30 min before ESWL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>indomethacin suppository</intervention_name>
    <description>100mg rectal indomethacin 30min before ESWL</description>
    <arm_group_label>Indomethacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glycerin Suppository</intervention_name>
    <description>30min before ESWL</description>
    <arm_group_label>Glycerin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  any patient with painful chronic pancreatitis and pancreatic stones (&gt; 5 mm in
             diameter) undergoing P-ESWL

          -  at least 18 years old

          -  provides informed consent

        Exclusion Criteria:

          -  no pain history during course of chronic pancreatitis

          -  contraindications to ESWL

          -  suspected or established malignancy

          -  pancreatic ascites

          -  receiving NSAIDs within 7 days

          -  contraindication to NSAIDs (including gastrointestinal hemorrhage within 4 weeks or
             renal dysfunction with serum creatinine &gt;120 μmol/L)

          -  presence of coagulopathy or received anticoagulation therapy within 3 days

          -  acute pancreatitis within 3 days

          -  known active cardiovascular or cerebrovascular disease

          -  pregnant or breastfeeding women

          -  without a rectum (ie, status post-total proctocolectomy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhuan Liao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changhai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhao-shen Li</last_name>
    <email>zhaoshen-li@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhuan Liao</last_name>
    <email>liaozhuan@smmu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhao-shen Li</last_name>
      <email>zhaoshen-li@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Zhuan Liao</last_name>
      <email>liaozhuan@smmu.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Liang-hao Hu</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yang-yang Qian</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 29, 2016</study_first_submitted>
  <study_first_submitted_qc>June 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2016</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Zhuan Liao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Extracorporeal Shock Wave lithotripsy(ESWL)</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>Indomethacin</keyword>
  <keyword>Chronic pancreatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Indomethacin</mesh_term>
    <mesh_term>Glycerol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

